ArticleAnnals of surgical oncology2026
Independent Dutch Validation Study of CP-GEP (Merlin Assay) for the Prediction of Nodal Metastasis and Long-Term Outcome in Patients with Primary Cutaneous Melanoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, sentinel lymph node biopsy (SLNB) is considered standard staging for patients with stage IB-II melanomas. Owing to recent systemic therapy advances, SLNB is once again being scrutinized. The aim of the current study was to validate the diagnostic accuracy of the clinicopathological gene expression profile (CP-GEP) for risk of sentinel node metastases and recurrence. PATIENTS AND
methodsSamples and clinical data of 252 patients with newly diagnosed clinical stage I/II melanoma between 2007 and 2015 were obtained. CP-GEP included eight target genes associated with tumor development (i.e., MLANA, GDF15, CXCL8, LOXL4, TGFBR1, ITGB3, PLAT, and SERPINE2) and two housekeeping genes in combination with clinicopathological variables, age, and Breslow thickness.
resultsThe median age was 57 years old, and 51.4% were female. The median Breslow thickness was 1.8 mm, and 53 patients (21.8%) had a positive SLNB. The median follow-up was 91 months. CP-GEP identified 68 (28%) patients as CP-GEP low risk and 175 (72%) as high risk. The sensitivity of CP-GEP was 92.5%, specificity was 33.7%, positive predictive value (PPV) was 28.0%, and negative predictive value (NPV) was 94.1% for all (T1-T4). The CP-GEP had the best performance in T1, with an NPV of 95.2% and an SLNB reduction rate (RR) of 80.8%. In the pT1b-pT2a melanomas with an NPV of 93.3% and a SLNB RR of 45.5% in terms of long-term survival, the 5-year recurrence-free survival (RFS) of CP-GEP low risk was 89.6% versus 76.8% for CP-GEP high-risk patients.
conclusionsCP-GEP demonstrated good prognostic performance, particularly for patients with pT1b-pT2a melanoma and thus could be considered a noninvasive alternative for a SLNB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.